multiple pik3ca mutation clonality correlates with outcomes in taselisib fulvestran... | rtcl.tv
Published 1 year ago • 26 plays • Length 0:30Download video MP4
Download video MP3
Similar videos
-
1:25
dr. jhaveri on results of taselisib in pik3ca-mutated metastatic solid tumors
-
7:49
asco: alpelisib plus fulvestrant for pik3ca-mutated breast cancer after failure of cdk4/6 inhibitors
-
1:59
dr. hurvitz on patient outcomes and pik3ca mutations
-
4:20
pik3ca mutations in her2-positive breast cancer
-
1:58
dr. tolaney on presence of pik3ca and esr1 mutations in monarch 2 trial in breast cancer
-
3:06
why do cancers have pik3ca mutations and how can they be targeted for cancer treatment?
-
12:58
update on pik3ca inhibitor (alpelisib) in lymphatic anomalies
-
57:31
pik3ca mutations in ccm - dr. mark kahn and dr. doug marchuk
-
1:31
dr. eskelund on study of tp53 mutations in mantle cell lymphoma
-
5:57
alpelisib in the management of pik3ca-mutated breast cancer
-
46:29
oncogene additivity in the pi3k pathway in cancer
-
1:45
animation: pik3ca gene mutation in pros
-
1:00
dr. chandarlapaty on role of the pi3k pathway in breast cancer
-
1:41
exploring the pi3kaktmtor pathway
-
22:48
showcase on detecting cancer mutations in liquid biopsy samples
-
0:58
flt3 mutation clearance rate in patients with newly diagnosed aml
-
5:43
cav1 shapes the matrix to guide metastasis
-
1:32
novel treatment combinations for flt3-mutated aml
-
5:15
brca-mutated triple-negative breast cancer